CORE IMAGE ANALYSIS FACILITY

本建议的总体目标是建立一个集中的 罗斯威尔公园纪念研究所的自动图像分析设备。 这 仪器将集中在格雷斯癌症药物中心， RPMI将由来自临床和基础研究的许多研究者使用 科学部门正在进行的联邦资助的研究项目。 这 将利用共同的工具来推进几个主要目标， 在RPMI的研究领域。 这些包括：1）开发用于以下的测定： 预测各种恶性肿瘤患者的治疗反应， 包括对人类的生物特性进行必要的表征， 肿瘤细胞; 2）细胞膜特性的研究，例如因子 影响融合效率的结构缺陷与 功能特性和膜内颗粒的描述， 恶性肿瘤沿着细胞中的表面标记;和3）遗传 评价细胞对治疗药物反应的研究， 特别提到耐药性和药物诱导的突变。 这 仪器将提高每个实验室识别 人类恶性肿瘤的基础和适当的治疗方法， 可能是针对个别患者的。 故知之，知之。 单分散肿瘤细胞的体外生长动力学应有助于 用于预测患者对抗癌药物的反应的测定法的设计 和辐射。 在药物开发领域，该文书将 促进药物的临床前表征，以确定潜在的 作为临床前毒理学和临床试验候选药物的抗癌剂 第一阶段评价。

The overall objective of this proposal is to establish a centralized automatic image analysis facility at Roswell Park Memorial Institute. This instrument which will be centralized in the Grace Cancer Drug Center at RPMI will be utilized by a number of investigators from clinical and basic science departments for ongoing Federally funded research projects. This shared instrument will be utilized to advance the goals of several major research areas at RPMI. These include: 1) the development of assays for prediction of response to therapy of patients with various malignancies, including necessary characterization of the biological properties of human tumor cells; 2) studies of cell membrane properties, such as factors affecting fusion efficiency, correlation of structural defects with functional properties, and description of intramembranous particles and surface labels in cells along various stages of malignancy; and 3) genetic studies to evaluate cellular responses to therapeutic drugs, with particular reference to drug resistance and drug-induced mutations. This instrument will enhance the capability of each laboratory to identify the bases of human malignancies and appropriate therapeutic approaches, where possible tailored to the individual patient. Thus, knowledge concerning the in vitro growth kinetics of monodispersed tumor cells should aid in the design of assays for prediction of patients' response to anticancer drugs and irradiation. In the area of drug development, this instrument would facilitate the preclinical characterization of drugs to identify potential anticancer agents as candidates for preclinical toxicology and clinical phase I evaluation.